Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma.
暂无分享,去创建一个
M. Taniwaki | Y. Ohashi | Y. Matsuno | S. Nakamura | M. Ogura | S. Mori | T. Kinoshita | K. Tobinai | K. Itoh | T. Igarashi | T. Hotta | T. Kinoshita | K. Aikawa | A. Hiraoka | Y. Kobayashi | K. Tsushita | Y. Matsuno | Y. Kobayashi | Yasuo Ohashi | Michinori Ogura | Shigeo Nakamura | Shigeo Mori | Tomomitsu Hotta
[1] M Taniwaki,et al. Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] B. E. C. Oiffier,et al. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .
[3] J. Vose,et al. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] S. Mori,et al. Practical Utility of the Revised European‐American Classification of Lymphoid Neoplasms for Japanese Non‐Hodgkin's Lymphomas , 2000, Japanese journal of cancer research : Gann.
[5] B. Coiffier,et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] C. Hardy,et al. Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin’s lymphoma after high-dose therapy and autologous peripheral stem cell transplantation , 1999, Bone Marrow Transplantation.
[7] J. Armitage,et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] J. Amess,et al. IDEC‐C2B8 anti‐CD20 (Rituximab) immunotherapy in patients with low‐grade non‐Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients , 1999, European journal of haematology.
[9] H. Okamoto,et al. Determination of antibodies to TT virus (TTV) and application to blood donors and patients with post-transfusion non-A to G hepatitis in Japan. , 1999, Journal of virological methods.
[10] K. Ohshima,et al. B-cell lymphoma of 708 cases in Japan: incidence rates and clinical prognosis according to the REAL classification. , 1998, Cancer letters.
[11] V. Diehl,et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. , 1998, Blood.
[12] M. Czuczman,et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] R. Levy,et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] M. Narabayashi,et al. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] T. Nishizawa,et al. A novel DNA virus (TTV) associated with elevated transaminase levels in posttransfusion hepatitis of unknown etiology. , 1997, Biochemical and biophysical research communications.
[16] D. Maloney,et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] M. Seto,et al. Immunohistochemical Analysis of Cyclin D1 Protein in Hematopoietic Neoplasms with Special Reference to Mantle Cell Lymphoma , 1994, Japanese journal of cancer research : Gann.
[18] H Stein,et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.
[19] M. Seto,et al. Monoclonal Antibody against PRADl/Cyclin Dl Stains Nuclei of Tumor Cells with Translocation or Amplification at BCL‐1 Locus , 1994, Japanese journal of cancer research : Gann.
[20] D. Czerwinski,et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. , 1994, Blood.
[21] Emili Montserrat,et al. A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[22] Y. Shimada,et al. Toxicity grading criteria of the Japan Clinical Oncology Group. The Clinical Trial Review Committee of the Japan Clinical Oncology Group. , 1993, Japanese journal of clinical oncology.
[23] T M Grogan,et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[24] L. Gordon,et al. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. , 1992, The New England journal of medicine.
[25] J. V. van Dongen,et al. Antibody L26 recognizes an intracellular epitope on the B-cell-associated CD20 antigen. , 1990, The American journal of pathology.
[26] C. Berard,et al. Lymphoproliferative diseases in Japan and Western countries: Proceedings of the United States--Japan Seminar, September 6 and 7, 1982, in Seattle, Washington. , 1983, Human pathology.
[27] E. McFadden,et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.
[28] T R Fleming,et al. One-sample multiple testing procedure for phase II clinical trials. , 1982, Biometrics.
[29] L. Nadler,et al. Characterization of a human B lymphocyte-specific antigen. , 1980, Journal of immunology.
[30] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[31] D.,et al. Regression Models and Life-Tables , 2022 .